Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERLIN: Mosunetuzumab for early relapse of follicular lymphoma
2022-500100-21-01Phase 2Authorised
- Sponsor
- Oslo University Hospital
- Start
- Feb 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of mosunetuzumab in follicular lymphoma (FL), sponsored by Oslo University Hospital. Primary endpoint: Progression-free survival. Planned start Feb 2023; status: authorised.
02
Drugs
mosunetuzumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2022-500100-21-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500100-21-01.